Results of the study of the Symplicity Spyral renal denervation system (RDN)

Medtronic plc, a global leader in healthcare technology, today announced primary endpoint results from the SPYRAL AFFIRM post-approval study of the Symplicity Spyral™ renal denervation (RDN) system. The study showed statistically significant and clinically meaningful blood pressure reductions at six months, including office, home, and 24-hour ambulatory blood pressure, with no increase in antihypertensive medications. The findings were presented as late-breaking data at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 annual meeting and simultaneously published in Circulation Cardiovascular Interventions.

SPYRAL AFFIRM is a prospective, multicenter, single-arm study designed with the United States (U.S.) Food and Drug Administration (FDA) to provide real-world evidence in patients with uncontrolled hypertension treated in the U.S. across diverse patient populations and clinically relevant subgroups, including women, Black American and Hispanic patients, and patients 65 and older. Six-month results in the U.S. primary endpoint cohort were compared with a prespecified performance goal.

At six months, the data showed:

  • Patients treated with Symplicity Spyral had significant reductions in blood pressure compared with baseline:
    • Office Systolic Blood Pressure (OSBP): -18.2 ± 22.0 mmHg (p<0.0001)
    • Home blood pressure: -9.4 ± 13.8 mmHg (p<0.0001)
    • 24-hour Ambulatory Blood Pressure (ABPM): -9.7 ± 16.8 mmHg (p<0.0001)
  • Similar blood pressure reductions were demonstrated in women, Black American and Hispanic patients, and patients 65 and older
  • There was no increase in antihypertensive medications through six months (3.6 ± 2.0 medications, unchanged from baseline).
  • The composite safety endpoint occurred in 2.1% of patients
  • Nearly nine out of 10 patients experienced a clinical benefit at six months; a separate pooled analysis replicated this clinical benefit at three years.1

Detailed information:

https://news.medtronic.com/2026-11-03-TCT26-Medtronic-Symplicity-blood-pressure-procedure-shows-significant-blood-pressure-drops-in-SPYRAL-AFFIRM-real-world-study